Type 2 diabetes and prediabetes prevalence in patients with different risk factor combinations in the NATION study

Código QR

Type 2 diabetes and prediabetes prevalence in patients with different risk factor combinations in the NATION study

BACKGROUND: Type 2 diabetes (T2D) is multifactorial disease. NATION epidemiological study may provide the information about the prevalence of T2D and prediabetic state in patients with different risk factor combinations in Russian population. AIMS: To evaluate the prevalence of T2D and prediabetic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ekaterina A. Shestakova, Elena Y. Lunina, Gagik R. Galstyan, Marina V. Shestakova, Ivan I. Dedov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	type 2 diabetes prediabetic state risk factors obesity family history age hypertension Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/f6ddda5308294ef9b371f0e108e87a02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

«DIARISK» — the first national prediabetes and diabetes mellitus type 2 risk calculator
por: Marina V. Shestakova, et al.
Publicado: (2021)

Phenotypes of prediabetes: pathogenesis and consequences for prediction and prevention of type 2 diabetes and cardiovascular diseases
por: Norbert Stefan
Publicado: (2019)

The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study)
por: Ivan I. Dedov, et al.
Publicado: (2016)

Metabolic syndrome: Contradictions and Concensuses (based on the materials of IV International Congress Prediabetes and Metabolic Syndrome, Madrid, 6-9 April 2011)
por: Olga Konstantinovna Vikulova
Publicado: (2011)

3rd International Congress of on prediabetes and metabolic syndrome, 1-4 April 2009, Nice
por: Elena Vladimirovna Pekareva, et al.
Publicado: (2009)

Obesity and type 2 diabetes: can we find a compromised treatment solution?
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation
por: Marina V. Shestakova, et al.
Publicado: (2017)

Relevance of results of the ADVANCE study for diabetes control in Russia
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
por: Ivan Ivanovich Dedov, et al.
Publicado: (2012)

New indications for exenatide therapy of type 2 diabetes mellitus
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2016)

The interrelationship and accumulation of cardiometabolic risk factors amongst young adults in the United Arab Emirates: The UAE Healthy Future Study
por: Fatima Mezhal, et al.
Publicado: (2021)

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
por: Elena Valer'evna Biryukova, et al.
Publicado: (2012)

Cardiorenal relationships in patients with type 2 diabetes mellitus: new data of the ADVANCE study
por: Marina Vladimirovna Shestakova
Publicado: (2009)

Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity
por: E. V. Pokrovskaya, et al.
Publicado: (2021)

The 3d World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, Prague, 13-16 May 2010
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Optimizing screening procedures for early detection of glycemic disorders
por: Inna Vladimirovna Misnikova, et al.
Publicado: (2014)

Sostoyanie pro- i antikoagulyantnykh sistempri ?prediabete? i sakharnom diabete 2 tipa
por: Anastasia Sergeevna Severina, et al.
Publicado: (2006)

Novosti s kongressa Amerikanskoy diabeticheskoy assotsiatsii
por: Gagik Radikovish Galstyan
Publicado: (2008)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Russian association of endocrinologist draft recommendation on insulin biosimilars using
por: I. I. Dedov, et al.
Publicado: (2021)

Obesity - a risk factor of renal pathology in patients with type 2 diabetes mellitus
por: Svetlana Alekseevna Savel'eva, et al.
Publicado: (2010)

Associations of functional and biochemical parameters of endothelial dysfunction in postmenopausal women with a different state of carbohydrate metabolism
por: Lyudmila Aleksandrovna Ruyatkina, et al.
Publicado: (2015)

Problema kontrolya kachestva diabetologicheskoy pomoshchi v Rossii po dannym na yanvar' 2007 g.
por: Ivan Ivanovich Dedov, et al.
Publicado: (2008)

National register of diabetes mellitus in Russian Federation.
por: Ivan Ivanovich Dedov, et al.
Publicado: (2015)

Metabolic characteristics and therapeutic potential of brown and ?beige? adipose tissues
por: Ekaterina Olegovna Koksharova, et al.
Publicado: (2014)

Novosti fundamental'nykh issledovaniy
por: Ivona Renata Yarek-Martynova, et al.
Publicado: (2008)

Course and treatment of diabetes mellitus in the context of COVID-19
por: Marina V. Shestakova, et al.
Publicado: (2020)

Glibenclamide therapy: pros and cons
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2011)

The prevalence of hypogonadism in men with type 2 diabetes mellitus in clinical practice
por: Galina A. Melnichenko, et al.
Publicado: (2019)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Novye vozmozhnosti v terapii SD 2 tipa: liraglutid - analog chelovecheskogo glyukagonopodobnogo peptida-1
por: Ivan Ivanovich Dedov, et al.
Publicado: (2008)

Endocrinology research centre statement about COVID-19 vaccination of diabetes mellitus patients
por: I. I. Dedov, et al.
Publicado: (2021)

On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
por: Aleksei N. Sumin, et al.
Publicado: (2016)

Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015)

Can simple intensification of therapy with modern two-phase insulin help in type 2 diabetes when target glycemia failed to be achieved withbasal insulin? Results of subanalysis in the PRESENT study
por: Ch S Yang, et al.
Publicado: (2009)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
por: Marina V. Shestakova
Publicado: (2019)

Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)